Hip surgery triggered atypical hemolytic uremic syndrome (aHUS) in a 49-year-old woman, who was successfully treated with plasma exchange, which is a blood-cleaning procedure, and kidney replacement therapy, according to a case study in India. A prompt diagnosis and multidisciplinary collaboration, as well as early and aggressive treatment of…
News
This year’s aHUS Awareness Day, Sept. 24, will highlight mental health issues important to people with atypical hemolytic uremic syndrome (aHUS) and their families. The annual event is being organized by the aHUS Alliance, an international umbrella organization that comprises patient groups and aHUS advocates to support patients,…
Soliris (eculizumab), an approved drug for atypical hemolytic uremic syndrome (aHUS), successfully treated a rare case of the disease in a girl, age 14 months, in China, according to a case study. After eight doses of the therapy, the levels of self-reactive antibodies against complement factor H —…
The kidney function of a woman with atypical hemolytic uremic syndrome (aHUS) was completely rescued with Soliris (eculizumab), but only after more than a year of treatment, a case study reports. “This case report supports the hypothesis that kidney pathological [disease] resolution in complement-mediated aHUS requires a long…
A U.S. woman with atypical hemolytic uremic syndrome (aHUS) has been in disease remission for 13 years while receiving treatment with C5 complement inhibitors after undergoing a kidney transplant, a new report details. According to the researchers, this is the longest reported case in the literature of an aHUS…
Long-term treatment with Ultomiris (ravulizumab) led to sustained clinical improvements for adults and children with atypical hemolytic uremic syndrome (aHUS), according to new two-year data from a pair of clinical trials. Patients in both age groups saw improvements in blood-related health factors and kidney function, and experienced less…
A girl in China had atypical hemolytic uremic syndrome (aHUS) and accompanying protein-losing enteropathy (PLE), a condition in which there is an excessive loss of proteins through the gastrointestinal tract. Treatment with Soliris (eculizumab) resolved both her aHUS-related kidney disease and PLE, according to a report. “Our case…
A toddler developed atypical hemolytic uremic syndrome (aHUS) while receiving chemotherapy to treat cancer, according to a case report. It’s easy for aHUS in cancer patients undergoing chemotherapy to be missed, since its symptoms are often mistakenly assumed to be complications caused by cancer or treatment, said the…
A woman developed atypical hemolytic uremic syndrome (aHUS) after receiving the first dose of a COVID-19 vaccine, according to a case study from Brazil. The researchers said the “connection of symptoms post-COVID-19 vaccination to aHUS … emphasizes the need for ongoing monitoring and research into vaccine-related complications.” The case…
The U.S. Food and Drug Administration (FDA) has approved Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab), as an atypical hemolytic uremic syndrome (aHUS) treatment. Epysqli, from Samsung Bioepis, has also been approved to treat people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that, like aHUS,…
Recent Posts
- Soliris enables successful second kidney transplant: Case study
- The struggles of losing weight when you’re chronically ill
- COVID-19 triggers aHUS in man following kidney transplant
- Heart complications were a puzzling part of my aHUS journey
- Inflammation of the pancreas may trigger aHUS, boy’s case shows
- Patients need more help to pay for rare disease treatment
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses